Bone Biologics Overview
- Year Founded
-
2004
- Status
-
Public
- Employees
-
2
- Stock Symbol
-
BBLG
- Investments
-
1
- Share Price
-
$0.33
- (As of Friday Closing)
Bone Biologics General Information
Description
Bone Biologics Corp a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. It is a clinical-stage entity. The production and marketing of its products and ongoing research and development activities are subject to extensive regulation by numerous governmental authorities in the United States.
Contact Information
Website
www.bonebiologics.comCorporate Office
- 2 Burlington Woods Drive
- Suite 100
- Burlington, MA 01803
- United States
Corporate Office
- 2 Burlington Woods Drive
- Suite 100
- Burlington, MA 01803
- United States
Bone Biologics Stock Performance
As of 13-Nov-2026, Bone Biologics’s stock price is $0.33. Its current market cap is $1.1M with 3.39M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.33 | $0.40 | $0.32 - $2.39 | $1.1M | 3.39M | 260K | -$1.02 |
Bone Biologics Financials Summary
As of 30-Sep-2026, Bone Biologics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | (2,664) | (3,446) | (1,250) | (2,038) |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (3,012) | (3,231) | (4,168) | (8,951) |
| Net Income | (2,842) | (3,109) | (4,112) | (8,949) |
| Total Assets | 6,432 | 5,796 | 3,861 | 3,738 |
| Total Debt | 0 | 0 | 0 | 0 |
Bone Biologics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Bone Biologics Comparisons
Industry
Financing
Details
Bone Biologics Competitors (6)
One of Bone Biologics’s 6 competitors is Regenerx, a Formerly VC-backed company based in Rockville, MD.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Regenerx | Formerly VC-backed | Rockville, MD | ||||
| Centrexion Therapeutics | Venture Capital-Backed | Boston, MA | ||||
| Aspect Biosystems | Venture Capital-Backed | Vancouver, Canada | ||||
| VivoSim Labs | Formerly VC-backed | San Diego, CA | ||||
| SYMATESE | Formerly PE-Backed | Chaponost, France |
Bone Biologics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Bone Biologics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Bone Biologics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Bone Biologics Acquisitions (1)
Bone Biologics’s most recent deal was a Merger/Acquisition with AFH Acquisition X. The deal was made on 16-Oct-2014.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| AFH Acquisition X | 16-Oct-2014 | Merger/Acquisition | Special Purpose Acquisition Company (SPAC) |
Bone Biologics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
36.29 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Healthcare
Industry
of 590
Rank
Percentile
Medical Devices
Subindustry
of 209
Rank
Percentile
Bone Biologics FAQs
-
When was Bone Biologics founded?
Bone Biologics was founded in 2004.
-
Where is Bone Biologics headquartered?
Bone Biologics is headquartered in Burlington, MA.
-
What is the size of Bone Biologics?
Bone Biologics has 2 total employees.
-
What industry is Bone Biologics in?
Bone Biologics’s primary industry is Biotechnology.
-
Is Bone Biologics a private or public company?
Bone Biologics is a Public company.
-
What is Bone Biologics’s stock symbol?
The ticker symbol for Bone Biologics is BBLG.
-
What is the current stock price of Bone Biologics?
As of 13-Nov-2026 the stock price of Bone Biologics is $0.33.
-
What is the current market cap of Bone Biologics?
The current market capitalization of Bone Biologics is $1.1M.
-
Who are Bone Biologics’s competitors?
Regenerx, Centrexion Therapeutics, Aspect Biosystems, VivoSim Labs, and SYMATESE are some of the 6 competitors of Bone Biologics.
-
What is Bone Biologics’s annual earnings per share (EPS)?
Bone Biologics’s EPS for 12 months was -$1.02.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
